Javascript must be enabled to continue!
Supervised Withdrawal Opioid Use Disorder Treatments
View through CrossRef
Abstract
Supervised opioid withdrawal (also referred to as detoxification or detox) is a medical treatment aimed at fully discontinuing opioid use in persons who are physically dependent on opioids. There is a long history of supervised withdrawal treatment programs in the United States, although the approach has varied wildly and to this day there is little guidance regarding best practices. Early approaches to supervised withdrawal favored an abrupt discontinuation of opioids rather than longer opioid tapers, though recent data support an extended approach. Withdrawal is a highly variable process with many decision points, including residential versus outpatient status, choice of withdrawal treatment and complementary/supportive interventions, duration of treatment, percent change in daily dose, and whether the withdrawal schedule is determined by the patient, provider, or both. Several treatments to help reduce withdrawal severity will be discussed. This chapter reviews the historical basis of withdrawal programs; the data supporting the aforementioned decision points; and the rationale, efficacy, and unique considerations for the different withdrawal methods. Outcomes following withdrawal programs, including resolution of medical comorbidities, overdose risk, and linkage to aftercare are also reviewed. Since the United States now has a formal indication of opioid withdrawal, this chapter also includes a discussion of important considerations for empirical trials of medications and/or other interventions for opioid withdrawal management. Future efforts to maximize the efficacy of withdrawal treatment, and importantly, to link individuals to long-term care (preferably with a medication for OUD) are important directions for future research and practice.
Oxford University Press
Title: Supervised Withdrawal Opioid Use Disorder Treatments
Description:
Abstract
Supervised opioid withdrawal (also referred to as detoxification or detox) is a medical treatment aimed at fully discontinuing opioid use in persons who are physically dependent on opioids.
There is a long history of supervised withdrawal treatment programs in the United States, although the approach has varied wildly and to this day there is little guidance regarding best practices.
Early approaches to supervised withdrawal favored an abrupt discontinuation of opioids rather than longer opioid tapers, though recent data support an extended approach.
Withdrawal is a highly variable process with many decision points, including residential versus outpatient status, choice of withdrawal treatment and complementary/supportive interventions, duration of treatment, percent change in daily dose, and whether the withdrawal schedule is determined by the patient, provider, or both.
Several treatments to help reduce withdrawal severity will be discussed.
This chapter reviews the historical basis of withdrawal programs; the data supporting the aforementioned decision points; and the rationale, efficacy, and unique considerations for the different withdrawal methods.
Outcomes following withdrawal programs, including resolution of medical comorbidities, overdose risk, and linkage to aftercare are also reviewed.
Since the United States now has a formal indication of opioid withdrawal, this chapter also includes a discussion of important considerations for empirical trials of medications and/or other interventions for opioid withdrawal management.
Future efforts to maximize the efficacy of withdrawal treatment, and importantly, to link individuals to long-term care (preferably with a medication for OUD) are important directions for future research and practice.
Related Results
A Large-Scale Observational Study on the Temporal Trends and Risk Factors of Opioid Overdose: Real-World Evidence for Better Opioids
A Large-Scale Observational Study on the Temporal Trends and Risk Factors of Opioid Overdose: Real-World Evidence for Better Opioids
Abstract
Background
The United States is in the midst of an opioid overdose epidemic. We evaluated the temporal trends and risk...
(
2R,6R
)-hydroxynorketamine facilitates extinction and prevents emotional impairment and stress-induced reinstatement in morphine abstinent mice
(
2R,6R
)-hydroxynorketamine facilitates extinction and prevents emotional impairment and stress-induced reinstatement in morphine abstinent mice
ABSTRACT
Opioid addiction is a pressing public health concern marked by frequent relapse during periods of abstinence, perpetuated by negative af...
Leftover Opioid Analgesics and Disposal Following Ambulatory Pediatric Surgeries in the Context of a Restrictive Opioid-Prescribing Policy
Leftover Opioid Analgesics and Disposal Following Ambulatory Pediatric Surgeries in the Context of a Restrictive Opioid-Prescribing Policy
BACKGROUND:
Opioid analgesics are commonly prescribed for postoperative analgesia following pediatric surgery and often result in leftover opioid analgesics in the home...
Unanticipated Benzodiazepine Withdrawal in the Context of an Adulterated Unregulated Opioid Supply in Vancouver, BC: A Case Series
Unanticipated Benzodiazepine Withdrawal in the Context of an Adulterated Unregulated Opioid Supply in Vancouver, BC: A Case Series
ABSTRACT
Background:
Novel psychoactive substance (NPS) benzodiazepines have emerged as frequent adulterants of the unregulated opioid supply in ...
Opioid use in young veterans
Opioid use in young veterans
Purpose: Data suggest an increase in prescription opioid abuse in recent years. Young veterans represent a group with major risk factors for prescription opioid abuse. The objectiv...
Assessing the Safety and Efficacy of Converting Adults with Sickle Cell Disease from Full Agonist Opioids to Buprenorphine
Assessing the Safety and Efficacy of Converting Adults with Sickle Cell Disease from Full Agonist Opioids to Buprenorphine
Abstract
Background: The management of pain in adults with sickle cell disease (SCD) is complex, with the intermingling of both acute vaso-occlusive events and chron...
Generalized Restless Body Syndrome: A case of opioid withdrawal- induced restlessness extending beyond the legs
Generalized Restless Body Syndrome: A case of opioid withdrawal- induced restlessness extending beyond the legs
Introduction:Restless leg syndrome (RLS) has been described in those undergoing opioid withdrawal as a factor exacerbating heroin dependence. RLS, however, has not been described a...
Comparison of Psychiatric Disorders in a Sample of Egyptian Patients with Methamphetamine versus Opioid Use Disorder: Rate and Addiction Severity
Comparison of Psychiatric Disorders in a Sample of Egyptian Patients with Methamphetamine versus Opioid Use Disorder: Rate and Addiction Severity
Abstract
Background
Methamphetamine use is markedly increasing worldwide. That widespread isn’t limited to high income countries...

